<![CDATA[In “Managing Tolerability and Setting Patients Up for Success with Cobenfy,” David Walling, PhD, delved into the key tolerability considerations for patients with schizophrenia transitioning to Cobenfy and how clinicians should proactively manage gastrointestinal side effects?]]>